Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2023 04:30 ET | Source: Transparency Market Research

Gene Vectors Market Predicted to Rise at a 12.6% CAGR until 2031, Reaching US$ 3.4 billion: TMR Report

Wilmington, Delaware, United States, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - TMR predicted that the gene vector market is likely to reach US$ 3.4 billion by 2031. Gene...
June 01, 2023 05:09 ET | Source: Rentschler Biopharma SE

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
September 14, 2022 07:00 ET | Source: Oxford Biomedica Solutions LLC

Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs

Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts – September 14, 2022: Oxford Biomedica Solutions LLC, an Oxford...
April 26, 2022 03:00 ET | Source: ViGeneron GmbH

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ...
January 18, 2021 02:00 ET | Source: ViGeneron GmbH

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...
January 05, 2021 02:00 ET | Source: ViGeneron GmbH

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...